Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | ACLY | P53396 | 5/20 | 0.43 |
| ▸ | PYGL | P06737 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12117652 | 0.93 | HDAC1 (0.48) | HDAC1ACLYPYGLBACE1KMT2A | |
| SCHEMBL12117847 | 0.92 | HDAC1 (0.45) | HDAC1ACLYPYGLBACE1KMT2A | |
| SCHEMBL12117928 | 0.89 | HDAC1 (0.48) | HDAC1ACLYPYGLBACE1KMT2A | |
| SCHEMBL12117774 | 0.88 | HDAC1 (0.47) | HDAC1ACLYPYGLBACE1HDAC2 | |
| SCHEMBL12117544 | 0.88 | MEN1 (0.51) | HDAC1ACLYKMT2AHDAC8MEN1 | |
| SCHEMBL12117763 | 0.87 | HDAC1 (0.47) | HDAC1ACLYPYGLBACE1KMT2A | |
| SCHEMBL12117777 | 0.87 | HDAC1 (0.44) | HDAC1ACLYPYGLBACE1KMT2A | |
| SCHEMBL12118072 | 0.87 | HDAC1 (0.46) | HDAC1ACLYPYGLSMN1; SMN2HDAC2 | |
| SCHEMBL12117779 | 0.86 | HDAC1 (0.43) | HDAC1ACLYPYGLBACE1KMT2A | |
| SCHEMBL12117929 | 0.85 | MAPT (0.43) | HDAC1ACLYPYGLBACE1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492582-B2 | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | COL14A1, COL2A1, COL1A1 | HDAC1 73/4885ACLY 295/4885PYGL 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.